Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported 24-week symptom data from the highest dose cohort in the Phase 1b/2a RESOLVE trial of EP-104GI for eosinophilic esophagitis. Cohort 9 (n=3) showed a mean SDI reduction of 4.0 points at 24 weeks (3 points = clinical remission).Pooled cohorts 4-9 showed clinical remission in 59% at 12 weeks (13/22), 76% at 24 weeks (13/17), and 67% at 52 weeks (6/9). No SAEs reported across 31 patients and >220 patient-months; no oropharyngeal candidiasis observed.

#EPRX Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

www.stocktitan.net/news/EPRX/eupraxia-pharm...

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for

#EPRX Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

www.stocktitan.net/news/EPRX/eupraxia-pharm...

Japan Meteorological Corporation Launches New Price Forecast for Demand-Supply Adjustment Market The Japan Meteorological Corporation has launched a new price forecast service for the demand-supply adjustment market, enhancing electricity trading strategies.

Japan Meteorological Corporation Launches New Price Forecast for Demand-Supply Adjustment Market #Japan #Tokyo #Energy_Market #Japan_Meteorological_Corporation #EPRX

Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy  At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health 1. At lower doses, patients maintained the improvements in tissue health 1 reported at week 12 out until week 36. Clinical remission 2 was achieved

#EPRX Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy 

www.stocktitan.net/news/EPRX/eupraxia-pharm...

Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026 Completed $80.5 million public offering supported by leading life science investors Cash

#EPRX Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/EPRX/eupraxia-pharm...

Breaking News: ( NASDAQ: #EPRX ) Peterson Capital Hosts Canada Growth Conference in Ireland

$70 Million Capital Raise: Eupraxia Pharmaceuticals Sets $5.50 Share Price in Major Public Offering Clinical-stage biotech Eupraxia offers 12.7M shares at $5.50, raising $70M for pipeline development. Includes 30-day option for additional 1.9M shares. Closing expected September 24.

#EPRX Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares

www.stocktitan.net/news/EPRX/eupraxia-pharm...

Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares Eupraxia Pharmaceuticals (NASDAQ:EPRX) has announced a proposed public offering of common shares. The company has filed a preliminary prospectus supplement to its base shelf prospectus for the offering, which includes a 30-day option for underwriters to purchase up to an additional 15% of shares.The offering will be jointly managed by Cantor and LifeSci Capital as book-running managers, with Bloom Burton acting as co-manager. The proceeds will primarily fund the company's product pipeline development, including ongoing clinical trials, regulatory submissions, and commercial preparation. Additional uses include R&D for pipeline candidates, business development, and general corporate purposes.The final terms and size of the offering will be determined at pricing, with completion subject to customary conditions including TSX and Nasdaq listing approvals.

#EPRX Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares

www.stocktitan.net/news/EPRX/eupraxia-pharm...

First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI Eupraxia Pharmaceuticals (NASDAQ:EPRX) has announced positive 1-year clinical results from its Phase 1b/2a RESOLVE trial evaluating EP-104GI for treating eosinophilic esophagitis (EoE). The trial demonstrated that 67% of patients in Cohort 5 (48mg dose) maintained clinical remission after 12 months.Key findings include significant tissue health improvements, with patients treated with 4mg per injection showing 47% improvement in grade and 44% in stage at week 36. The drug maintained steady plasma levels through 52 weeks, below typical asthma inhaler levels. Importantly, no serious adverse events or oral/gastrointestinal candidiasis were reported.The company believes EP-104GI could potentially offer a revolutionary once-yearly treatment option, administered during routine annual endoscopy procedures, presenting a significant advantage over current daily oral steroids or weekly biologics.

#EPRX First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI

www.stocktitan.net/news/EPRX/first-set-of-1...

Eupraxia's EoE Drug Shows 9-Month Sustained Benefits as Phase 2b Trial Launches Clinical-stage biotech advances EP-104GI treatment for eosinophilic esophagitis with positive 9-month data and Phase 2b trial initiation. $19.8M cash runway into Q3 2026. See details.

#EPRX Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/EPRX/eupraxia-pharm...

Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis Eupraxia Pharmaceuticals (NASDAQ:EPRX) has initiated the Phase 2b placebo-controlled portion of its RESOLVE clinical trial for EP-104GI, a treatment for eosinophilic esophagitis (EoE). The study will enroll minimum 60 patients across 25 global sites, evaluating two active doses against placebo over 12 months.The trial's first active dose of 120 mg was selected based on encouraging early data from cohort 8, showing the largest decline in Peak Eosinophil Count and lowest EoEHSS scores at 4 weeks. The study will assess tissue health, symptom scores, and safety, with placebo patients eligible to receive EP-104GI after six months. Topline data is expected by Q3 2026, with additional Phase 2a data releases planned for September and November 2025.

#EPRX Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis

www.stocktitan.net/news/EPRX/eupraxia-doses...

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) held its Annual General and Special Meeting on June 2, 2025, where shareholders approved all proposed items. All six board nominees were successfully elected with high approval rates, led by James A. Helliwell and Joseph Freedman with 99.997% votes in favor. Shareholders also approved the appointment of KPMG LLP as auditors, the 2025 Omnibus Incentive Plan, and the re-pricing of certain non-executive employee stock options. Eupraxia is advancing its DiffuSphere™ technology platform, designed for targeted drug delivery with extended-release capabilities. The company has two key clinical programs: EP-104GI in Phase 1b/2a for EoE treatment and EP-104IAR, which recently completed a successful Phase 2b trial for knee osteoarthritis pain, meeting its primary endpoint and three secondary endpoints.

#EPRX Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

www.stocktitan.net/news/EPRX/eupraxia-pharm...

Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results Eupraxia Pharmaceuticals (NASDAQ/TSX: EPRX) reported its Q1 2025 financial results and provided updates on its EP-104GI clinical trial for Eosinophilic Esophagitis (EoE). The company highlighted positive nine-month data from the Phase 1b/2a RESOLVE trial, showing sustained treatment outcomes with a single 48mg dose. Financial results showed a net loss of $6.8 million compared to $6.2 million in Q1 2024. The company maintains a strong cash position of $27.5 million as of March 31, 2025, with runway extending to Q3 2026. Key developments include the appointment of Alex Rothwell as CFO and continued positive trial results with no serious adverse events reported. The company is monitoring potential impacts of proposed U.S.-Canada tariffs on its operations.

#EPRX Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/EPRX/eupraxia-pharm...

Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported sustained positive outcomes from its RESOLVE Phase 1b/2a trial of EP-104GI for eosinophilic esophagitis (EoE) treatment. After 9 months, patients receiving 48mg EP-104GI showed sustained or improved treatment outcomes. Key findings include:- All patients reported reduced symptom severity, with up to 100% reduction and average 65% improvement in SDI scores- 56% reduction in tissue health (EoEHSS Stage) and 45% reduction in Grade score- 77% mean decrease in eosinophil counts with 52% remission rate- One patient maintained complete histologic remission from 3 through 9 monthsThe 6-month data for the 64mg cohort showed up to 86% reduction in symptom severity. The company plans to release additional long-term data with higher doses in Q3 2025.

#EPRX Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI

www.stocktitan.net/news/EPRX/eupraxia-pharm...

Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results Eupraxia Pharmaceuticals (NASDAQ/TSX: EPRX) reported Q4 2024 financial results, highlighting positive developments in its clinical trials. The company posted a net loss of $7.5 million for Q4 2024, an improvement from the $10.6 million loss in Q4 2023. Cash position strengthened to $33.1 million as of December 31, 2024, up from $19.3 million year-over-year.Key highlights include compelling data from the Phase 1b/2a RESOLVE trial for EP-104GI in treating eosinophilic esophagitis, with improved tissue health and symptom reduction outcomes at higher doses. The company successfully raised C$44.5 million through a private placement, extending its funding runway into Q3 2026.The company is monitoring potential impacts of proposed 25% U.S. tariffs on Canadian goods and planned Canadian retaliatory tariffs, as it sources API and manufactures clinical supplies in the U.S.

#EPRX Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

www.stocktitan.net/news/EPRX/eupraxia-pharm...

Eupraxia's EoE Drug Achieves 94% Reduction in Key Inflammatory Markers Without Steroid Side Effects Promising clinical data shows significant symptom relief and tissue improvement with increasing dosage. No serious adverse events or common steroid-related side effects reported.

#EPRX Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

www.stocktitan.net/news/EPRX/eupraxia-pharm...

Veteran Capital Markets Executive Returns as Eupraxia CFO to Drive Clinical Pipeline Growth Experienced finance leader Alex Rothwell rejoins Eupraxia as CFO, bringing 25+ years of capital markets expertise to advance key clinical programs EP-104GI and EP-104IAR.

#EPRX Eupraxia Pharmaceuticals Announces CFO Succession

www.stocktitan.net/news/EPRX/eupraxia-pharm...

#EPRX New #Pharmacokinetic data shows their diffusphere technology effectively targets drug release, minimizing systemic exposure. A significant step forward in the eosinophilic esophagitis program.

#biotech #pharma

NEWS: ( NASDAQ: #EPRX ) Eupraxia's DiffuSphere(TM) Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

#StockMarket #News

#EPRX Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

www.stocktitan.net/news/EPRX/eupraxia-s-dif...

#EPRX Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

www.stocktitan.net/news/EPRX/eupraxia-pharm...